News

Dr Alberto Villarejo has joined Memorial Publio Cordón as a scientific adviser to its Alzheimer’s programmes

5 min read
Dr Rocío García-Ramos, head of the Memory Disorders Unit, alongside Dr Alberto Villarejo Galende, scientific adviser.

The neurologist, a specialist in cognitive impairment and neurodegenerative diseases, brings his clinical and research expertise to the Memory Disorders Unit, headed by Dr Rocío García-Ramos, which runs programmes for the early detection, diagnosis and anti-amyloid treatment of Alzheimer’s disease.

Memorial Publio Cordón Hospital has appointed Dr Alberto Villarejo Galende as scientific adviser to its specialist programmes on Alzheimer’s disease, run by the Memory Disorders Unit under the direction of Dr Rocío García-Ramos, head of the hospital’s Neurology department.

Dr Villarejo’s appointment brings his expertise in the study of neurodegenerative diseases, diagnostic biomarkers and new therapeutic strategies at a time of significant scientific advances that are transforming the approach to Alzheimer’s. His role will focus on providing scientific advice for the programmes and assessing the clinical and safety criteria associated with new diagnostic and treatment options.

Dr Villarejo is Head of the Neurology Department at the 12 de Octubre University Hospital in Madrid and an associate professor of Neurology at the Complutense University of Madrid. Throughout his career, he has served as principal investigator in over 30 international phase II and III clinical trials, particularly those relating to the diagnosis and new therapies for Alzheimer’s disease.

His appointment forms part of the development of a care model that aims to identify the disease in its early stages, establish increasingly accurate diagnoses and assess the available treatment options in accordance with each patient’s individual characteristics.

From early diagnosis to new treatment options for Alzheimer’s

The Memory Disorders Unit at Memorial Publio Cordón organises its specialist care through three programmes designed to address different clinical situations, ranging from the onset of the first cognitive changes to the assessment of disease-modifying treatments.

The Early Alzheimer’s Screening Programme offers an initial assessment of memory and other cognitive functions, incorporating tools such as the p-tau217 blood biomarker. Its aim is to identify possible signs of impairment and determine when further investigation is warranted.

Where there are persistent symptoms, results requiring clarification or suspicion of a neurodegenerative disease, the Alzheimer’s Diagnosis Programme combines neurological and neuropsychological assessment with neuroimaging tests and specific biomarkers. This process enables an individualised diagnosis to be established and guides decisions regarding follow-up and treatment.

In addition to these two areas, there is the Alzheimer’s Anti-Amyloid Treatment Programme, designed to assess the suitability of new disease-modifying therapies in carefully selected patients at an early stage of the disease. The programme covers diagnostic confirmation, the assessment of potential risks, and specific clinical and radiological monitoring during treatment.

These three programmes, under the clinical direction of Dr García-Ramos and with scientific advice from Dr Villarejo, enable a coordinated approach to the various decisions raised by the disease, from the first suspicions right through to the possibilities for therapeutic intervention.

Scientific rigour and safety in relation to new anti-amyloid therapies

One area in which scientific advice takes on particular importance is the introduction of treatments such as lecanemab and donanemab, which are designed to reduce the accumulation of beta-amyloid protein in the brain. These therapies have been shown to slow the progression of cognitive and functional decline in certain patients with early-stage Alzheimer’s disease, although they are not curative and are not suitable for everyone diagnosed with the condition.

The hospital had already announced the inclusion of these new therapies in its Alzheimer’s programme, which incorporates neurological assessment, confirmation of amyloid pathology, the selection of candidates and the monitoring of potential complications.

For Dr Rocío García-Ramos, therapeutic progress must be accompanied by particularly rigorous implementation:

‘We are witnessing one of the most significant advances of recent decades in the treatment of Alzheimer’s, but our responsibility as doctors is not merely to incorporate innovation, but to know when, how and to whom we should offer it.’

The complexity of these decisions requires an assessment of both the expected clinical benefit and the potential adverse effects, including amyloid-related imaging abnormalities (ARIA), which require specific follow-up via magnetic resonance imaging.

Dr Villarejo’s research experience in biomarkers, clinical trials and treatments for Alzheimer’s is particularly valuable in this context, where diagnostic accuracy and appropriate patient selection are essential.

As Dr García-Ramos points out:

‘The true success of these therapies will not lie solely in our ability to administer them, but in our ability to use them effectively. We must avoid raising false expectations, rigorously select patients and ensure that every decision is made with their benefit and safety in mind.’

The arrival of these treatments therefore represents an opportunity that must be approached with realistic expectations. The aim is to slow the progression of the disease in patients who meet the established clinical criteria, whilst maintaining an individual assessment of the benefits and risks.

Specialist care that combines clinical experience and research

The appointment of Dr Villarejo as a scientific adviser reflects the growing importance of translating research advances into clinical practice in accordance with safety criteria and scientific evidence.

Under the leadership of Dr García-Ramos, the Memory Disorders Unit brings together specialised neurological assessment, neuropsychology, neuroradiology and other diagnostic and clinical care areas necessary to study each case and guide medical decisions.

This organisation takes on particular significance in light of new possibilities for detection using biomarkers and the development of treatments that require a precise understanding of both the disease and the patient’s clinical condition.

We are opening a door that for many years seemed closed. Precisely for this reason, we have a duty to get it right. The rigorous and responsible use of these treatments will be essential to consolidate their benefits and help ensure that, in the future, a greater number of patients can access them.

With the involvement of Dr Villarejo, Memorial Publio Cordón is consolidating a model of care for Alzheimer’s that combines its team’s clinical expertise, specialised scientific advice and access to advanced diagnostic and therapeutic tools, with rigour and patient safety as fundamental principles.

Share this news item
Previous news item Next news item
Call Book now